- 29 -

WO 2005/079747

5

10

15

PCT/EP2004/014478

CLAIMS

1. An pharmaceutical preparation in the form of an aqueous solution comprising:

- (a) a nonsteroidal anti-inflammatory drug (NSAID) also having analgesic activity;
- (b) a biologically compatible buffering organic amine provided with a free or monosubstituted amino group or a mixture thereof, in a quantity suitable for buffering the pH of the preparation within the range specified below;
- (c) a pH within a range of 6.5 to 8.0; and
- (d) pharmaceutical grade water;
 wherein the NSAID (a) is flurbiprofen and/or diclofenac;
 and the biologically compatible buffering organic amine
 (b) is D-glucamine, meglumine, trometamol (tris buffer) or
 a mixture thereof.
- 2. A pharmaceutical preparation to claim 1, wherein the flurbiprofen is in the form of a racemate or one of its enantiomers selected from R-(-)flurbiprofen and S-(+)flurbiprofen.
- 3. A pharmaceutical preparation according to claim 1
 25 or 2, which comprises (a) flurbiprofen in a quantity of
 1.5 mg/ml to 8.0 mg/ml, preferably 2.5 mg/ml; and/or

- 30 -

diclofenac in a quantity of 0.5 mg/ml to 1.5 mg/ml, preferably 0.74 mg/ml.

- 4. A pharmaceutical preparation according to any one of the preceding claims, which has a pH of 7.0 to 7.5.
- 5. A pharmaceutical preparation according to any one of the preceding claims, which comprises D-glucamine in a quantity of 0.35 mg/ml to 1.12 mg/ml; meglumine in a quantity of 0.40 mg/ml to 2.4 mg/ml; and/or trometamol in a quantity of 0.10 mg/ml to 0.75 mg/ml.
- 6. A pharmaceutical preparation according to any one of the preceding claims, which comprises the biologically compatible buffering organic amine (b) in a quantity suitable for buffering the pH of the solution within the range of 7.0 to 7.5.
- 7. A pharmaceutical preparation according to any one of the preceding claims, which additionally comprises the following auxiliary ingredients:
 - (e) a mild disinfectant; and/or
 - (f) one or more preservatives; wherein:
- (e) the mild disinfectant comprises at least one of cetylpyridinium chloride, optionally in a quantity of 1.0 mg/ml to 6.0 mg/ml, optimally of 5.0 mg/ml;

- 31 -

glycyrrhizic acid or a salt thereof, optionally in a quantity of 0.8 mg/ml to 1.2 mg/mg, optimally of 1.0 mg/ml;

(f) the preservative comprises at least one of methyl p-hydroxybenzoate, optionally in a quantity of 0.25 mg/ml to 1.15 mg/ml;

propyl p-hydroxybenzoate, optionally in a quantity of 0.03 mg/ml to 0.15 mg/ml;

disodium calcium edentate, optionally in a quantity of 0.1 mg/ml to 1.0 mg/ml;

sodium benzoate, optionally in a quantity of 0.2 mg/ml to 5.0 mg/ml.

8. A pharmaceutical preparation according to any one
15 of the preceding claims, which additionally comprises
at least one further auxiliary ingredient selected from
a viscosity agent, a sweetening agent, a fluidising
agent, a thickening agent, a colouring agent and a
natural essence or flavouring agent.

20

25

5

10

9. A pharmaceutical preparation according to claim 8, wherein the further auxiliary ingredient is selected from at least one of glycerol, sorbitol, xylitol, ethyl alcohol, castor oil 40 polyethoxylate, saccharin sodium, acesulfame potassium, mint essence, natural mint flavour, natural peach flavour and patent blue V-E131, E-124.

- 32 -

10. A pharmaceutical preparation according to any one of the preceding claims for the treatment of inflammation of the mouth and pharynx, in particular of the mouth, the throat and the gums.

5

10

15

- 11. A pharmaceutical preparation according to any one of the preceding claims in the form of a mouthwash for spraying, preferably with a dispensed volume for each unit dose of between 100 microlitres (0.1 ml) and 300 microlitres (0.3 ml), preferably of 200 microlitres (0.2 ml).
- 12. A packaged pharmaceutical preparation containing the pharmaceutical preparation according to any one of claims 1 to 11, equipped with a dosing pump.
- 13. A process for the production of the pharmaceutical preparation according to any one of claims 1 to 11, which comprises
- 20 i) dissolving preservative(s) in a solution;
 - ii) dissolving the selected NSAID in water or a water/ethyl alcohol mixture and buffering with the organic amine to the specified pH value;
- iii) adding any auxiliary ingredients to the

 25 solution of step i), and mixing the solution of step i)
 with the solution of NSAID and organic amine from step
 ii);

- 33 -

(iv) making up to volume (or weight) with water, if necessary, adjusting the pH to the prescribed value with addition of organic amine.